The Sensex rose by 147 points, closing above the 81,000 mark, while the Nifty ended above 24,800, reflecting positive trends in global markets. Three stocks caught the market’s attention: Paytm, which dropped by 3.14%; Nucleus Software, which fell by 6.04%; and Aarti Drugs, which increased by 6%.
Here’s what experts suggest for these stocks:
Paytm:
After hitting a low of 310 in May 2024, Paytm’s share price nearly doubled, reaching a high of 605. However, it now appears overpriced and may face a pullback. The stock has support levels around 500-480. For long-term investors, it’s a good pick, but it’s better to wait for a price drop before buying. If the price dips to 500 or 470, consider buying with a stop-loss of 450. The target is 600-700 within the next 8-10 months.
Nucleus Software:
Nucleus Software reached a peak of 1800 in January 2024, but has since dropped to around 1094. For the past 8 months, it has been trading in a range, struggling to rise above 1600 and likely to dip towards its support level of 1100. Given its low trading volume, the stock is expected to stay within this range. Investors are advised to book profits at the current levels rather than buying more.
Aarti Drugs:
After hitting a low of 431 in March 2024, Aarti Drugs surged to 600, showing a strong uptrend. However, after a 40% gain from its low, it is likely to see some profit-taking at current levels. The stock is considered overbought, so it’s better to wait for a dip before buying. Consider buying if it falls to 540 or 520, with a stop-loss of 480. The target range is 620-680 over the next 10-12 months.
Investors should carefully consider these recommendations and watch for any dips in the market to make informed decisions.
Disclaimer: The views and investment tips expressed by investment experts on Sharepriceindia.com are their own and not those of the website or its management. Sharepriceindia.com advises users to check with certified experts before taking any investment decisions.
